SOT102, A Novel CLDN18.2-Targeting Antibody-Drug Conjugate With Strong Therapeutic Potential in Solid Tumors

Time: 12:00 pm
day: Day Two


  • SOT102 is based on a novel proprietary CLDN18.2 specific monoclonal antibody, conjugated to PNU-159682
  • Evaluate how SOT102 demonstrated strong antitumor activity in mouse
  • PDX models of gastric, pancreatic and other solid tumors, including those with low target expression
  • Gain an update on a Phase 1/2 study in patients with gastric and pancreatic cancer that is planned to start in early 2022